Search clinical trials for: sorafenib and cisplatin

Total 270473 results

Bayer

Completed

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

China, Taiwan
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Liver Cancer

United States
Swedish Medical Center
Bayer; Amgen

Completed

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Lung Cancer

United States
Bayer

Completed

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Kidney Diseases
Bayer

Completed

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Carcinoma, Hepatocellular

Germany
Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
Beijing Shenogen Biomedical Co., Ltd
The First Affiliated Hospital with Nanjing Medical University; General Hospital... and other collaborators

Terminated

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Hepatocellular Carcinoma (HCC)

China
University of Wisconsin, Madison
Bayer

Completed

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Carcinoma, Non Small Cell Lung

United States
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (SUCCESS)

Carcinoma, Hepatocellular

China
Bayer

Completed

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NEXST)

Carcinoma, Renal Cell

Poland
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (SARAH)

Liver Carcinoma

France
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Hepatocellular Carcinoma

Taiwan, Hong Kong, China, Thailand, Korea, Republic of, Singapore, Japan
Bayer

Completed

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Canada
Bayer
Amgen

Completed

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Cancer | Carcinoma, Non-Small Cell Lung

United States, Germany
Chinese Society of Lung Cancer

Completed

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Non-Small Cell Lung Cancer

China
Medical Research Council

Completed

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Kidney Cancer

United Kingdom
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
Istituto Clinico Humanitas

Completed

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Sarcoma, Soft Tissue

Italy
NYU Langone Health

Recruiting

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Carcinoma

United States
Emory University
OSI Pharmaceuticals

Terminated

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Liver Cancer

United States
Peking University Cancer Hospital & Institute

Unknown

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Melanoma

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Bayer

Completed

Relative Bioavailability of Sorafenib Tablet for Oral Suspension

Biological Availability

Germany
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
Bayer

Completed

BAY43-9006 - Phase II in Advanced Breast Cancer

Breast Cancer | Breast Neoplasms

Italy, Germany
Castleton University

Withdrawn

Cannabidiol Effects on Cardiovascular System and Exercise Responses

Healthy

United States
Sinocelltech Ltd.

Active, not recruiting

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Mina Alpha Limited

Active, not recruiting

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)

Hepatocellular Carcinoma | Liver Cancer

Taiwan, Singapore, United Kingdom
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Esophageal Cancer | Gastroesophageal Junction Cancer

United States
Bayer
Amgen

Completed

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms

France, China, Korea, Republic of, United States, Spain, Russian Federation, United Kingdom, Netherlands, Sweden, Austria, Italy, Bulgaria, Poland, Saudi Arabia, Germany, Japan, Belgium, Denmark
Bayer

Completed

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib in Elderly mRCC

Carcinoma, Renal Cell

China
Bayer

Completed

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Canada, Singapore, United States, Germany, Australia, Austria, Korea, Republic of, Italy, Taiwan

Search clinical trials for: sorafenib and cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations